Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis | Zendy

Marco Merli | Zendy; Laura Galli | Zendy; Letizia Marinaro | Zendy; Alessandra Ariaudo | Zendy; Emanuela Messina | Zendy; Caterina UbertiFoppa | Zendy; Antonella Castagna | Zendy; Antonio D’Avolio | Zendy; Adriano Lazzarin | Zendy; Stefano Bonora | Zendy; Hamid Hasson | Zendy

Open Access

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis

Author(s) -

Marco Merli,

Laura Galli,

Letizia Marinaro,

Alessandra Ariaudo,

Emanuela Messina,

Caterina UbertiFoppa,

Antonella Castagna,

Antonio D’Avolio,

Adriano Lazzarin,

Stefano Bonora,

Hamid Hasson

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw492

Subject(s) - dolutegravir , rilpivirine , simeprevir , sofosbuvir , medicine , gastroenterology , virology , hepatitis c virus , viral load , ribavirin , human immunodeficiency virus (hiv) , virus , antiretroviral therapy

To evaluate the plasma trough concentrations ( C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research